Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

doi:10.1016/S0140-6736(20)30925-9

About:

This article is published in The Lancet.The article was published on 2020-10-17 and is currently open access. It has received 5802 citations till now. The article focuses on the topics: Disease burden & Years of potential life lost.

PDF

Open Access

More filters

TL;DR: CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high- income countries.

...read moreread less

TL;DR: The largest declines in risk exposure from 2010 to 2019 were among a set of risks that are strongly linked to social and economic development, including household air pollution; unsafe water, sanitation, and handwashing; and child growth failure.

...read moreread less

TL;DR: The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascul...

...read moreread less

TL;DR: In this paper , the authors presented the most comprehensive estimates of AMR burden to date, which can be divided into five broad components: number of deaths where infection played a role, proportion of infectious deaths attributable to a given infectious syndrome, proportionof infectious syndrome deaths attributed to a particular pathogen, the percentage of a given pathogen resistant to an antibiotic of interest, and the excess risk of death or duration of an infection associated with this resistance.

...read moreread less

TL;DR: This study provides the first comprehensive assessment of the global burden of AMR, as well as an evaluation of the availability of data, and estimates aggregated to the global and regional level.

...read moreread less

PDF

Open Access

More filters

TL;DR: The pace of progress achieved between 1990 and 2016 varied, with markedly faster improvements occurring between 2000 and 2016 for many countries in sub-Saharan Africa and southeast Asia, whereas several countries in Latin America and elsewhere saw progress stagnate after experiencing considerable advances in the HAQ Index between1990 and 2000.

...read moreread less

TL;DR: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD.

...read moreread less

TL;DR: The findings suggest that continued trends in female educational attainment and access to contraception will hasten declines in fertility and slow population growth, and suggest a shifting age structure in many parts of the world.

...read moreread less

TL;DR: Drug repurposing is a common approach to AD drug development and represents 39% of trials in the current AD pipeline, and most of the repurposed agents are generic and a variety of intellectual property strategies have been adopted to enhance their economic value.

...read moreread less

Collapse

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Citations

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study

Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

References

Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: A systematic analysis from the Global Burden of Disease Study 2016

Alzheimer's disease drug development pipeline: 2018.

Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study.

Repurposed agents in the Alzheimer’s disease drug development pipeline

International Classification of Diseases (ICD)

Related Papers (5)

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Global, regional, and national incidence, prevalence, andyears lived with disability for 354 diseases and injuries for195 countries and territories, 1990–2017: a systematicanalysis for the Global Burden of Disease Study 2017

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013